a year ago
SRPT
AnalystsGil BlumGil Blum's Stock Forecasts
AnalystsGil Blum
Sectors:
Industries:
Analyst Ranking
Top 3%
#116 out of 5134 analysts
Average Return
+13.78%
Win Rate
41%180 out of 443
Risk vs Reward
Poor
Good
Gil Blum's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Celcuity IncCELC | +1,044.42% | $9.23 | $105.63 | 2025-04-10 - 2025-12-05 | Buy |
Celcuity IncCELC | +1,037.03% | $9.29 | $105.63 | 2025-03-31 - 2025-12-05 | Buy |
Celcuity IncCELC | +904.09% | $10.52 | $105.63 | 2025-05-14 - 2025-12-05 | Buy |
Celcuity IncCELC | +739.00% | $12.59 | $105.63 | 2025-02-05 - 2025-12-05 | Buy |
Celcuity IncCELC | +691.24% | $13.35 | $105.63 | 2025-06-29 - 2025-12-05 | Buy |
Gil Blum Analyst Color
Get additional color on Gil Blum's coverage of popular stocks
2 years ago
AUTL
2 years ago
AUTL
Gil Blum's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Solid Biosciences IncSLDB | 1 | Buy | $16.00 | +177.30% | Initiates Coverage On | 2 days ago |
Absci CorpABSI | 6 | Buy | $7.00 | +95.53% | Maintains | 23 days ago |
Crispr Therapeutics AgCRSP | 26 | Buy | $80.00 | +40.65% | Maintains | a month ago |
Geron CorpGERN | 23 | Buy | $4.00 | +205.34% | Maintains | a month ago |
Nurix Therapeutics IncNRIX | 27 | Buy | $26.00 | +43.73% | Reiterates | a month ago |
Tscan Therapeutics IncTCRX | 8 | Buy | $6.00 | +455.56% | Maintains | a month ago |
Autolus Therapeutics PLCAUTL | 31 | Buy | $10.00 | +545.16% | Reiterates | a month ago |
Celcuity IncCELC | 21 | Buy | $70.00 | -33.73% | Reiterates | 2 months ago |
Taysha Gene Therapies IncTSHA | 31 | Buy | $10.00 | +98.02% | Reiterates | 2 months ago |
Artiva Biotherapeutics IncARTV | 7 | Buy | $18.00 | +435.71% | Reiterates | 2 months ago |
Amicus Therapeutics IncFOLD | 2 | Buy | $14.00 | +41.41% | Upgrades | 3 months ago |
Recursion Pharmaceuticals IncRXRX | 25 | Buy | $8.00 | +69.85% | Reiterates | 3 months ago |
Novabridge BiosciencesNBP | 17 | Buy | $6.00 | +43.54% | Reiterates | 3 months ago |
Generation Bio CoGBIO | 18 | Buy | $15.00 | +181.43% | Reiterates | 4 months ago |
Nkarta IncNKTX | 17 | Buy | $10.00 | +455.56% | Reiterates | 4 months ago |
Sarepta Therapeutics IncSRPT | 33 | Hold | $50.00 | +124.62% | Downgrades | 5 months ago |
Mereo Biopharma Group PLCMREO | 19 | Buy | $5.00 | +142.72% | Maintains | 5 months ago |
Rocket Pharmaceuticals IncRCKT | 21 | Hold | $42.00 | +1,165.06% | Downgrades | 6 months ago |
Cartesian Therapeutics IncRNAC | 23 | Buy | $40.00 | +481.40% | Maintains | 7 months ago |
Immunocore Holdings PLCIMCR | 14 | Buy | $71.00 | +83.08% | Reiterates | 8 months ago |
Arcellx IncACLX | 22 | Buy | $105.00 | +50.95% | Reiterates | a year ago |
Shattuck Labs IncSTTK | 13 | Hold | $8.00 | N/A | Downgrades | a year ago |
Nextcure IncNXTC | 9 | Buy | $48.00 | N/A | Reiterates | a year ago |
G1 Therapeutics IncGTHX | 17 | Buy | $6.00 | N/A | Maintains | a year ago |
Gamida Cell LtdGMDAQ | 8 | Buy | $6.00 | N/A | Reiterates | 2 years ago |
Cti Biopharma CorpCTIC | 5 | Buy | $9.00 | N/A | Reiterates | 3 years ago |
Tectonic Therapeutic IncTECX | 4 | Buy | $72.00 | N/A | Reiterates | 3 years ago |
Fate Therapeutics IncFATE | 1 | Hold | N/A | N/A | Initiates Coverage On | 3 years ago |
Spyre Therapeutics IncSYRE | 1 | Buy | $225.00 | N/A | Maintains | 4 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.